Skip to content
Search

Latest Stories

Submit Guest Post

India's Ola raises $500m ahead of IPO

India's Ola raises $500m ahead of IPO

INDIAN ride-hailing firm Ola, backed by Japan's SoftBank Group Corp, said on Friday (9) private equity firms Temasek and Warburg Pincus are investing $500 million in the startup ahead of its planned initial public offering (IPO).

Ola did not give details on its IPO plans but said that it continues to scale up its business across various categories and geographies.


"Over the last 12 months, we have made our ride-hailing business more robust, resilient and efficient. With strong recovery post lockdown and a shift in consumer preference away from public transportation," Chairman and Group Chief Executive Officer Bhavish Aggarwal said in a statement.

Ola was hit hard last year when the pandemic-related lockdowns forced people to stay at home, forcing it to cut about 35 per cent of its workforce and halting 95 per cent of its business.

The company's latest round of funding comes at a time when prominent Indian startups are hitting the public market through IPOs to cash in on a flush of liquidity by foreign funds and the country's new-age retail investors, with 22 companies debuting so far in 2021.

In May, Ola's early investor Matrix Partners India sold a part of its stake for $75 million cash at a valuation of $3-3.5 billion.

Recently, Temasek and Warburg Pincus have been increasing their exposure to technology startups in India.

While New York-based private equity firm Warburg Pincus invested in audio appliances brand boAt earlier this year, Singapore government-owned investment company Temasek has backed education firm Upgrad and online meat delivery startup Licious, among others.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less